The severity of biomarkers of non-alcoholic hepatic steatosis in patients with obesity, stable exertional angina and stenosing atherosclerosis of the carotid arteries

The aim of the study: to study the prognostic value of biomarkers of non-alcoholic liver steatosis in assessing the expression of atherosclerosis of the general carotid artery in patients with stable angina and obesity.

Materials and methods of research. Two groups of patients were formed during the study. Group I was made up of patients with stable angina with concomitant obesity (n = 24). Group II (n = 35) were stable angina patients with normal body mass index (BMI). Liver function, carbohydrate and lipid exchanges, duplex scanning results of the extracranial brachyocephalic artery (BCA) were evaluated, and biomarkers of steatosis were calculated: hepatic steatosis index (HSI), TyG indices, BARD, BAAT, VAI. Ultrasound of the liver (ultrasound) was performed on all patients.

Results. 100% of group I patients showed liver steatosis based on ultrasound. Biomarkers of liver steatosis (HSI, TyG, BARD, BAAT, VAI) were more severe in group I patients and confi rmed the presence of liver steatosis. Also among the patients of group I found: more pronounced disorders of functional state of liver, more signifi cant hypertriglyceridemia. More signifi cant atherosclerotic changes in OCA were detected in group I patients. Atherosclerotic plaques were more frequently found in group I patients compared to group II patients (70.8% vs 40%). The proportion of patients with signifi cant stenosis (> 50% of the vessel lumen) in group I was signifi cantly higher and amounted to 33.3%.

Conclusion. In patients with stable angina combined with obesity, in case of liver functional parameters disorder, pronounced hypertriglyceridemia, non-invasive biomarkers of liver non-alcoholic steatosis screening allow confi rming the presence of early morphological liver changes, as well as predicting more pronounced atherosclerotic changes of the common carotid artery.

1. Sanyal A. J. NASH: A global health problem. Hepatology Research. 2011;41(7):670-674. DOI: 10.1111/i.1872-034X.2011.00824.X.

2. Farrell G. C, barter C. Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. J. Hepatol. 2006; 43: 99-112. DOI: 10.1002/hep.20973.

3. Ivashkin V. T., Drapkina O. M., Maiev I. V., et al. The prevalence of nonalcoholic fatty liver disease in patients of outpatient practice in the Russian Federation: results of the DIREG 2 trial. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015; 6: 31-41. (In Russ).

4. Lonardo A., Ballestri S., Marchesini G., Angulo P. and Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Digestive and Liver Disease. 2015; 47: 181-190. DOI:10.1016/j.dld.2014.09.020.

5. Targer G., Day C. P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. The new England Journal of Medicine. 2010; 363:1341-1350. DOI: 10.1056/NEJMra0912063.

6. Adams L. A., Lymp J. F., St Sauver J., Sanderson S. O., Lindor K. D., Feldstein A., Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005; 129:113-121. DOI: 10.1053/j.gastro.

7. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, Younossi Z. M. Long-term follow-up of patients with nonalcoholic fatty liver. Clinical Gastroenterology and Hepatology. 2009; 7:234-238. DOI: 10.1016/j.cgh.2008.11.005.

8. Cardiovascular prevention 2017. National Guidelines. Russian Journal of Cardiology. 2018; (6):7-122. (In Russ.). DOI:10.15829/1560-4071-2018-6-7-122.

9. EASL-EASD-EASO. Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016; 64: 1388-1402.

10. Cadranel J. F. Good clinical practice guidelines for fine needle aspiration biopsy of the liver: past, present and future. Gastroenterologie Clinique Biologique. 2002; 26:823-824. DOI: GCB-10-2002-26-10-0399-8320-101019-ART1.

11. Bravo A.A, Sheth S.G, Chopra S. Liver biopsy. The new England Journal of Medicine. 2001;344 (7):495-500. DOI: 10.1056/NEJM200102153440706.

12. Fedchuk L., Nascimbeni F., Pais R., Charlotte F. et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment. Pharm. Ther. 2014; 40: 1209-1222. DOI:10.1111/apt.12963

13. Williams B., Mancia G., Spiering W. et al. 2018 ESC/ ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. European Heart Journal. 2018; 39 (33): 3021-3104. DOI: 10.1093/eurheartj/ehy339.

14. Amato M. C., Giordano C., Galia M., Criscimanna A., Vitabile S. et al. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiomet-abolic risk. Diabetes Care. 2010; 33: 920-922.

15. Adams L.A., George J., Bugianesi E., et al. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology. 2011; 26: 536-1543. DOI: 10.1111/j.1440-1746.2011.06774.x.

16. Harrison S. A., Oliver D., Arnold H. L., Gogia S., Neuschwander-Tetri B. A. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008; 57: 1441-1447. DOI: 10.1136/gut.2007.146019.

17. Drapkina O. M., Korneeva O. N. Continuum of non-alcoholic fatty liver disease: from hepatic steatosis to cardiovascular risk. Ration Pharmacother Cardiol. 2016;12(4):424-429. (In Russ.). DOI: 10.20996/1819-6446-2016-12-4-424-429.

18. Verrijken A., Francque S., Mertens I., Prawitt J., Caron S., Hubens G., et al. Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2014; 59:121-129. DOI: 10.1002/hep.26510.

19. Kumar R. et al. Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations. Journal of Clinical and Translational Hepatology. 2020;8: 76-86. DOI: 10.14218/JCTH.2019.00051.

20. Oni E.T, Agatston A.S, Blaha M.J, Fialkow J, Cury R, Sposito A, et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis. 2013; 230:258-267. DOI: 10.1016/уатеросклероз.2013.07.052.